- Home
- FIHL vs RCKT Comparison
FIHL vs RCKT Comparison
Compare FIHL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIHL
- RCKT
- Stock Information
- Founded
- FIHL 2014
- RCKT 1999
- Country
- FIHL Bermuda
- RCKT United States
- Employees
- FIHL N/A
- RCKT N/A
- Industry
- FIHL
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- FIHL
- RCKT Health Care
- Exchange
- FIHL Nasdaq
- RCKT Nasdaq
- Market Cap
- FIHL 2.1B
- RCKT 1.9B
- IPO Year
- FIHL 2023
- RCKT N/A
- Fundamental
- Price
- FIHL $17.43
- RCKT $17.13
- Analyst Decision
- FIHL Buy
- RCKT Strong Buy
- Analyst Count
- FIHL 9
- RCKT 9
- Target Price
- FIHL $20.50
- RCKT $53.22
- AVG Volume (30 Days)
- FIHL 302.1K
- RCKT 731.3K
- Earning Date
- FIHL 11-12-2024
- RCKT 11-04-2024
- Dividend Yield
- FIHL 2.30%
- RCKT N/A
- EPS Growth
- FIHL N/A
- RCKT N/A
- EPS
- FIHL 3.82
- RCKT N/A
- Revenue
- FIHL $2,151,300,000.00
- RCKT N/A
- Revenue This Year
- FIHL N/A
- RCKT N/A
- Revenue Next Year
- FIHL $13.62
- RCKT $300.20
- P/E Ratio
- FIHL $4.55
- RCKT N/A
- Revenue Growth
- FIHL N/A
- RCKT N/A
- 52 Week Low
- FIHL $11.55
- RCKT $15.98
- 52 Week High
- FIHL $20.53
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- FIHL 46.22
- RCKT 46.41
- Support Level
- FIHL $17.24
- RCKT $17.05
- Resistance Level
- FIHL $17.74
- RCKT $17.75
- Average True Range (ATR)
- FIHL 0.34
- RCKT 0.72
- MACD
- FIHL -0.04
- RCKT 0.06
- Stochastic Oscillator
- FIHL 28.79
- RCKT 40.23
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a global (re)insurance company. It classify the business into three underwriting segments, namely Bespoke, Specialty and Reinsurance. Specialty primarily comprises property D&F, energy, marine and aviation lines. Bespoke primarily comprises credit and political risk and other tailored solutions for clients including transactional liabilities and credit insurance. Reinsurance primarily comprises property reinsurance.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.